In addition, there have been numerous development of myosin targeted drugs, such as Mavacamten capsules (the first oral heart-specific allosteric inhibitor of cardiac myosin, treatment for hypertrophic cardiomyopathy, which reduced the ATPase activity of cardiac myosin heavy chain, inhibited myocardial overcontraction, and increased diastolic compliance); Aficamten (CK-3773274) (a cardiac myosin inhibitor, treatment for hypertrophic cardiomyopathy, which directly bound to cardiac myosin, reduced myocardial contractility and excessive contraction). The gene discussed is MYH14; the disease is hypertrophic cardiomyopathy.